Levodopa/Carbidopa/Entacapone Orion Европейски съюз - български - EMA (European Medicines Agency)

levodopa/carbidopa/entacapone orion

orion corporation - l-dopa, карбидопа, энтакапон - Паркинсонова болест - Нервна система - Леводопа/carbidopa/entacapone Орион е показан за лечение на възрастни пациенти с болестта на Паркинсон и край на доза моторни колебания не стабилизирани на леводопа / допа-декарбоксилаза (ddc)-инхибитор лечение.

Lapozan 5 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lapozan 5 mg film - coated tablets

medochemie ltd., - Оланзапин - 5 mg film - coated tablets

Lapozan 10 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lapozan 10 mg film - coated tablets

medochemie ltd., - Оланзапин - 10 mg film - coated tablets

Lapozan 5 mg orodispersible tablets България - български - Изпълнителна агенция по лекарствата

lapozan 5 mg orodispersible tablets

medochemie ltd., - Оланзапин - 5 mg orodispersible tablets

Lapozan 10 mg orodispersible tablets България - български - Изпълнителна агенция по лекарствата

lapozan 10 mg orodispersible tablets

medochemie ltd. - Оланзапин - 10 mg orodispersible tablets

Apo - Infect spag. Peka   България - български - Изпълнителна агенция по лекарствата

apo - infect spag. peka  

pekana-naturheilmittel gmbh -  

Apo - go Pen 10 mg/ml solution for injection България - български - Изпълнителна агенция по лекарствата

apo - go pen 10 mg/ml solution for injection

britannia pharmaceuticals limited - 10 mg/ml solution for injection

Apo - go Ampoules 10 mg/ml solution for injection or infusion България - български - Изпълнителна агенция по лекарствата

apo - go ampoules 10 mg/ml solution for injection or infusion

britannia pharmaceuticals limited - 10 mg/ml solution for injection or infusion

Apo - go Pfs 5 mg/ml solution for infusion in pre - filled syringe България - български - Изпълнителна агенция по лекарствата

apo - go pfs 5 mg/ml solution for infusion in pre - filled syringe

britannia pharmaceuticals limited - 5 mg/ml solution for infusion in pre - filled syringe

Zolsketil pegylated liposomal Европейски съюз - български - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.